Date published: 2026-1-20

1-800-457-3801

SCBT Portrait Logo
Seach Input

4-(p-Iodophenyl)butyric acid (CAS 27913-58-2)

0.0(0)
Write a reviewAsk a question

Alternate Names:
4-Iodobenzenebutanoic acid
Application:
4-(p-Iodophenyl)butyric acid is A useful halogenated carboxylic acid for proteomics research
CAS Number:
27913-58-2
Purity:
≥95%
Molecular Weight:
290.10
Molecular Formula:
C10H11IO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

4-(p-Iodophenyl)butyric acid, known as 4-IPBA, is a significant organic compound extensively explored for its diverse applications in scientific research. Serving as a synthetic, non-steroidal agent, 4-(p-Iodophenyl)butyric acid showcases its value through its ability to inhibit aromatase—an enzyme for estrogen synthesis. Scientific investigations have delved into the potential uses of 4-(p-Iodophenyl)butyric acid, establishing its role as an aromatase inhibitor—an invaluable tool for studying the effects of estrogen within the body. Furthermore, researchers have examined its capacity to modulate the activity of specific enzymes, notably cytochrome P450 enzymes, involved in drug and compound metabolism. Additionally, studies have explored the potential of 4-(p-Iodophenyl)butyric acid in inhibiting the growth of specific cancer cell types. In the realm of aromatase inhibition, 4-(p-Iodophenyl)butyric acid achieves its effects by binding to the enzyme′s active site, effectively impeding the conversion of androgens to estrogens. Its action as a modulator of enzymes, such as cytochrome P450, stems from its binding to the active site, ultimately influencing the enzyme′s activity. The multifaceted properties of 4-(p-Iodophenyl)butyric acid make it a valuable asset in scientific research, facilitating investigations into estrogen-related processes, enzyme modulation, and potential anti-cancer applications.


4-(p-Iodophenyl)butyric acid (CAS 27913-58-2) References

  1. 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.  |  Choy, CJ., et al. 2017. Theranostics. 7: 1928-1939. PMID: 28638478
  2. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG.  |  Wang, Z., et al. 2018. Bioconjug Chem. 29: 2309-2315. PMID: 29865797
  3. 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.  |  Banerjee, SR., et al. 2019. Eur J Nucl Med Mol Imaging. 46: 2545-2557. PMID: 31399803
  4. Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC.  |  Yoon, S., et al. 2019. Mol Ther Nucleic Acids. 18: 142-154. PMID: 31546149
  5. The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride.  |  Hausner, SH., et al. 2020. Mol Imaging Biol. 22: 1543-1552. PMID: 32383076
  6. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.  |  Xu, M., et al. 2022. J Nucl Med. 63: 952-958. PMID: 34593598
  7. The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of 67Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.  |  Xu, J., et al. 2022. Cancer Biother Radiopharm. 37: 47-55. PMID: 34762521
  8. Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.  |  Stroet, MCM., et al. 2022. Cancers (Basel). 14: PMID: 35205609
  9. Therapeutic Efficacy of 177Lu-Labeled A20FMDV2 Peptides Targeting ανβ6.  |  Huynh, TT., et al. 2022. Pharmaceuticals (Basel). 15: PMID: 35215341
  10. Synthesis and biological evaluation of Al[18F]-NOTA-IPB-PDL1P as a molecular probe for PET imaging of PD-L1 positive tumors.  |  Sun, P., et al. 2022. Bioorg Chem. 122: 105682. PMID: 35278777
  11. Novel albumin-binding photothermal agent ICG-IBA-RGD for targeted fluorescent imaging and photothermal therapy of cancer.  |  Yu, C., et al. 2021. RSC Adv. 11: 7226-7230. PMID: 35423244
  12. A Comparison of Evans Blue and 4-(p-Iodophenyl)butyryl Albumin Binding Moieties on an Integrin αvβ6 Binding Peptide.  |  Davis, RA., et al. 2022. Pharmaceutics. 14: PMID: 35456579
  13. Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αvβ3-Targeted Radionuclide Therapy.  |  Yang, G., et al. 2022. Pharmaceutics. 14: PMID: 35890224
  14. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.  |  Reissig, F., et al. 2022. Theranostics. 12: 7203-7215. PMID: 36438496
  15. Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers.  |  Murce, E., et al. 2023. R Soc Open Sci. 10: 220950. PMID: 36908985

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

4-(p-Iodophenyl)butyric acid, 1 g

sc-232297
1 g
$78.00

4-(p-Iodophenyl)butyric acid, 5 g

sc-232297A
5 g
$298.00